The Vanguard Group, Inc. Updates on Avadel Pharmaceuticals Stake

The Vanguard Group, Inc. has filed a Form 8.3, disclosing its interest in Avadel Pharmaceuticals plc. As of December 30, 2025, Vanguard reported owning 5,864,542 ordinary shares of Avadel, representing 5.97% of the company's issued share capital.

This filing, under Rule 8.3 of the Irish Takeover Panel Act, is part of standard procedure amidst a potential takeover scenario. It outlines Vanguard's significant position in Avadel, but does not indicate any exempt fund manager involvement. No additional parties are connected to this disclosure.

Vanguard's latest transactions include purchasing 610 shares and selling 306 shares, each at $21.54 per share. The company reported no derivative-related dealings or other agreements affecting its securities in Avadel.